Sotiburafusp alfa Drug Asset Due Diligence Report 2026: Clinical, IP, Market, Deals, and Go/No-Go
This Sotiburafusp alfa Drug Asset Due Diligence Report was built with PatSnap Life Sciences MCP workflows. Drug & Asset MCP establishes identity, ownership and stage; Clinical Trials MCP checks design, endpoints and readouts; Company & Deal Intelligence MCP reconstructs transaction precedent. Explore the MCP servers used in this report.
Decision date: 23 July 2026. Currency fields are presented in US$ millions as returned by the deal dataset. This is a screening memorandum, not legal, medical, patent or investment advice.
Executive recommendation: GO
Decision memo
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
The central underwriting question is whether Sotiburafusp alfa can convert its Bispecific antibody, Antibody fusion proteins profile and PDL1 x VEGF biology into clinically meaningful differentiation while preserving an investable safety, IP and commercial position.
1. Asset identity and development status
| Asset | Sotiburafusp alfa (query alias: Sotiburafusp alfa) |
|---|---|
| Modality / target | Bispecific antibody, Antibody fusion proteins; PDL1 x VEGF; PDL1 inhibitors, VEGF inhibitors |
| Highest global status | Phase 3 |
| Originator | Huabo Biopharm Co Ltd., Zhejiang Huahai Pharmaceutical Co., Ltd. |
| Active developers | Zhejiang Huahai Pharmaceutical Co., Ltd., Shanghai Huaaotai Biopharmaceutical Co., Ltd., Huabo Biopharm Co Ltd. |
The MCP disease footprint includes Advanced Endometrial Carcinoma, Endometrioid Carcinoma, Recurrent Endometrial Cancer. The highest-phase flag is a useful orientation point, but the licensing case depends on indication-level evidence and rights, not the global label alone.
2. Clinical program: design and endpoint audit
| Registry | Phase | Status | Enrollment | Lead primary endpoint |
|---|---|---|---|---|
| NCT07383116 | Phase 3 | Not yet recruiting | 500 | Progression-free survival (PFS) |
| CTR20262401 | Phase 3 | 进行中 （尚未招募） | 333 | Not disclosed |
| CTR20260016 | Phase 3 | 进行中 （招募中） | 10 | Not disclosed |
The trial set should be diligenced for randomization, comparator relevance, endpoint hierarchy, analysis population, multiplicity, geographic mix and readout timing. For early-stage studies, safety and dose selection can be as decision-critical as response rate.
Reproduce the asset-to-trial workflow with PatSnap MCP
3. Clinical readouts: what is known
A phase II study of HB0025 (a PD-L1/VEGF bispecific antibody) in combination with chemotherapy as first-line treatment for non–small cell lung cancer (NSCLC).
Phase 2; n=125; evaluation: Positive. Reported fields: ORR = 65.6 % ; ORR = 84.5 %
PD-L1/VEGF双抗缩瘤能力惊艳，会逆袭依沃西单抗吗？
临床2期; n=not disclosed; evaluation: 积极. Reported fields: ORR = 100 % ; ORR = 84.3 % ; ORR = 85.4 %
华海药业PD‑L1/VEGF双抗肺癌一线数据惊艳,已推至子宫内膜癌三期
临床2期; n=125; evaluation: 积极. Reported fields: PR = 62.3 % ; PR = 82.8 % ; -
These fields are structured evidence signals, not a substitute for statistical review. The next diligence pass should reconcile denominators, confidence intervals, follow-up, censoring, dose cohorts and treatment-emergent toxicity against the original abstract, registry and protocol.
4. Market and competitive position
Sotiburafusp alfa addresses Advanced Endometrial Carcinoma, Endometrioid Carcinoma, Recurrent Endometrial Cancer. Commercial attractiveness rests on addressable biomarker-positive patients, treatment-line placement, duration, administration burden, pricing and displacement of entrenched standards. The modality—Bispecific antibody, Antibody fusion proteins—must demonstrate a benefit large enough to offset class-specific safety and operational costs.
The strongest market-validation signal in this screen is partner behavior: 148 matched transaction record(s) indicate that sophisticated counterparties have assigned strategic value to the asset or its rights. That does not establish net present value; probability of success, remaining R&D spend, royalties, cost sharing and territorial scope still need modeling.
5. Transaction precedent and economics
Transaction-scope note: No direct asset-specific transaction was returned. The table below shows target-level comparable: PDL1 x VEGF records as comparable precedents only.
| Date | Transaction | Phase at deal | Disclosed economics |
|---|---|---|---|
| 2026-06-26 | CStone Pharma joins hands with Arrotex to commercialise Sugemalimab across Australia and New Zealand | Approved | Financial terms not disclosed |
| 2026-02-18 | BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License | Not disclosed | Financial terms not disclosed |
| 2026-01-06 | Instil Bio’s Subsidiary Discontinues Clinical Development of AXN-2510 and Terminates License and Collaboration Agreement with ImmuneOnco | Phase 1/2 | US$50.0M upfront; US$2,000.0M milestones |
Headline values are not directly comparable. Diligence should normalize upfront cash, equity, development and sales milestones, tiered royalties, opt-in mechanics, cost sharing, change-of-control clauses and geography.
6. IP and freedom-to-operate screen
No asset-specific patent-application milestone appeared in the returned milestone slice. That absence is not a freedom-to-operate conclusion; a dedicated family, claim, ownership, expiry, and legal-status search remains mandatory before signing.
The claim chart should separately test composition or sequence coverage, formulation and dosing, indication and biomarker claims, combinations, manufacturing know-how, prosecution history, term extensions and third-party blocking rights. Confirm that licensed patents, data and know-how track every granted territory and field.
7. Principal risks and diligence gates
- Class crowding and differentiation versus other PD-(L)1/VEGF agents
- Immune and anti-angiogenic safety, including bleeding and cardiovascular risk
- Biomarker strategy, indication selection, and head-to-head endpoint execution
Cross-functional diligence should also test CMC comparability, supply chain, pharmacovigilance, regulatory correspondence, data integrity, investigator concentration, partner obligations and change-of-control restrictions.
8. Final go/no-go memorandum
GO
Advance diligence: development maturity and available evidence support continued investment, subject to indication-specific safety, IP, and commercial gates.
Required pre-signing gates: reproduce key efficacy analyses; complete an indication-specific safety review; run a full patent-family and freedom-to-operate search; model risk-adjusted economics by territory; and reconcile all rights, sublicenses and encumbrances.
Build your next drug-asset diligence workflow with PatSnap Life Sciences MCP Servers
Data provenance: PatSnap Drug & Asset MCP, Clinical Trials MCP, and Company & Deal Intelligence MCP; accessed 23 July 2026. Counts and status fields may change as source records update.
